Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Guilin Three Gorges Pharmaceutical is a prominent Chinese pharmaceutical manufacturer and a subsidiary of China Resources Sanjiu Medical & Pharmaceutical. Established in 1969, the company specializes in the production of active pharmaceutical ingredients (APIs) and finished dosage forms, with a strong focus on oncology and cardiovascular health. Its flagship product, L-asparaginase, is a critical therapeutic for acute lymphoblastic leukemia, making the company a significant player in the specialized biologics market. Additionally, the firm produces a range of cardiovascular treatments, including amiodarone hydrochloride, and maintains high-standard GMP manufacturing facilities in Guilin. As part of the China Resources Group, it leverages extensive distribution networks to supply essential medicines across China and international markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Guilin Three Gorges Pharmaceutical.